Inhibikase Therapeutics
IKT
22 hedge funds and large institutions have $2.49M invested in Inhibikase Therapeutics in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 6 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
0.62% less ownership
Funds ownership: 2.83% → 2.21% (-0.62%)
8% less funds holding
Funds holding: 24 → 22 (-2)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
61% less capital invested
Capital invested by funds: $6.33M → $2.49M (-$3.84M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Antara Capital
New York
|
+$98.3K |
| 2 |
Koshinski Asset Management
Decatur,
Illinois
|
+$64.3K |
| 3 |
Renaissance Technologies
New York
|
+$32.9K |
| 4 |
William Blair & Company
Chicago,
Illinois
|
+$24.6K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$14.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KC
Kepos Capital
New York
|
-$1.04M |
| 2 |
LCM
Lynwood Capital Management
Toronto,
Ontario, Canada
|
-$178K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$147K |
| 4 |
ACM
ACT Capital Management
Wayne,
Pennsylvania
|
-$137K |
| 5 |
BlackRock
New York
|
-$76K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
UBS Group
Zurich,
Switzerland
| – | -$8K | -852 | Closed |
|
27
Wells Fargo
San Francisco,
California
| – | +$12 | +2 | +10% |
|
28
Citigroup
New York
| – | +$490 | +83 | New |
|
IKT Hedge Fund Activity: Q2 2022 in Review
22 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Inhibikase Therapeutics (IKT) for Q2 2022, worth a combined $2.49M — down 61% from $6.33M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of IKT and 4 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 8 added.
The largest buyer was Antara Capital, adding an estimated $98.3K. The largest seller was Kepos Capital, exiting entirely with an estimated $1.04M sold.
- 22 institutional investors held Inhibikase Therapeutics (IKT) as of Q2 2022, down from 24 in Q1 2022.
- Funds reported $2.49M of Inhibikase Therapeutics stock for Q2 2022, down 61% quarter-over-quarter.
- 4 funds opened new Inhibikase Therapeutics positions in Q2 2022 and 6 closed out, a net change of -2 holders.
- The largest Inhibikase Therapeutics buyer in Q2 2022 was Antara Capital, an estimated $98.3K added.
- The largest Inhibikase Therapeutics seller in Q2 2022 was Kepos Capital, an estimated $1.04M sold.
Based on aggregated 13F filings for Q2 2022.